心泰医疗2024年度报告

Stock Code 股份代號 : 2291 年 度 報 告Annual Report2024 Contents Definitions2Corporate Information9Financial Highlights12Chairman’s Statement14Management Discussion and Analysis17Biographies of Directors,49Supervisors and Senior ManagementReport of the Directors60Report of the Board of Supervisors88Environmental, Social and93Governance ReportCorporate Governance Report167Independent Auditor’s Report203Consolidated Balance Sheet212Consolidated Income Statement216Consolidated Statement of Cash Flows220Consolidated Statement of Changes in223Owners’ EquityNotes to the Consolidated225Financial StatementsParticulars of Investment Properties379Five-Year Financial Summary3802912141749608893167203212216220223225379380 Definitions Inthis annual report,the following expressions have themeanings set out below unless the context requires otherwise: Definitions Definitions Definitions Corporate Information BOARD OF DIRECTORS Executive Director Ms. Chen Juan(Chairman) Non-Executive Directors 20243 1202412 9202412 9 Ms. Zhang Yuxin(re-designated on March 1, 2024)Mr. Fu ShanMr. Zhu Guanfu(appointed on December 9, 2024)Mr. Zheng Guorui(resigned on December 9, 2024) Independent Non-Executive Directors 20247 2620247 26 Ms. Chan Ka Lai VanessaMr. Zheng YufengMr. Zheng Junwei(appointed on July 26, 2024)Mr. Liu Daozhi(resigned on July 26, 2024) SUPERVISORS Mr. Wang XinglinMs. Wang XiaoyongMr. Qian Weidong AUDIT COMMITTEE Ms. Chan Ka Lai Vanessa(Chairperson)Mr. Zhu Guanfu(appointed on December 9, 2024)Mr. Zheng YufengMr. Zheng Guorui(resigned on December 9, 2024) 202412 9202412 9 REMUNERATION COMMITTEE 20247 2620247 26 Mr. Zheng Yufeng(Chairperson)Ms. Chen JuanMr. Fu ShanMs. Chan Ka Lai VanessaMr. Zheng Junwei(appointed on July 26, 2024)Mr. Liu Daozhi(resigned on July 26, 2024) Corporate Information NOMINATION COMMITTEE Ms. Chen Juan(Chairperson)Mr. Zhu Guanfu(appointed on December 9, 2024)Ms. Chan Ka Lai VanessaMr. Zheng YufengMr. Zheng Junwei(appointed on July 26, 2024)Mr. Liu Daozhi(resigned on July 26, 2024)Mr. Zheng Guorui(resigned on December 9, 2024) 202412 920247 2620247 26202412 9 JOINT COMPANY SECRETARIES 20248 2220248 22 Mr. Qin XueMr. Li Kin Wai(appointed on August 22, 2024)Ms. Ko Mei Ying(resigned on August 22, 2024) AUTHORIZED REPRESENTATIVES 20248 2220243 120248 2220243 1 Ms. Chen JuanMr. Li Kin Wai(appointed on August 22, 2024)Ms. Ko Mei Ying(appointed on March 1, 2024and resigned on August 22, 2024)Ms. Zhang Yuxin(resigned on March 1, 2024) LEGAL ADDRESS IN THE PRC 25841201 Room 201Building 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC ADDRESS OF HEAD OFFICE IN THE PRC 2584115 1/F, 5/FBuilding 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 33191918 Room 1918, 19/F, Lee Garden One33 Hysan AvenueCauseway Bay, Hong Kong Corporate Information AUDITORS BDO China Shu Lun Pan Certified Public Accountants LLP LEGAL ADVISORS ••• As to Hong Kong lawWilson Sonsini Goodrich & Rosati Haiwen & Partners COMPLIANCE ADVISOR 811 Halcyon Capital Limited11/F, 8 Wyndham StreetCentralHong Kong HONG KONG SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKS Bank of ShanghaiChina Merchants BankIndustrial and Commercial Bank of ChinaBank of Ningbo http://www.scientechmed.com/ COMPANY WEBSITE http://www.scientechmed.com/ 2022118 LISTING DATE November 8, 2022 STOCK CODE Financial Highlights 20231231326.644.4%20241231471.6 –Revenue increased by 44.4% from RMB326.6 million forthe year ended December 31, 2023 to RMB471.6 millionfor the year ended December 31, 2024. –Gross profit increased by 46.7% from RMB289.1 millionforthe year ended December 31,2023 to RMB424.0million for the year ended December 31, 2024. 20231231289.146.7%20241231424.0 –Research and development expenses decreased by 6.6%from RMB62.1 million for the year ended December 31,2023 to RMB58.0 million for the year ended December 31,2024. 2023123162.16.6%2024123158.0 20231231151.462.2%20241231245.6 –Netprofit attributable to shareholders of the parentcompany increased by 62.2% from RMB151.4 million forthe year ended December 31, 2023 to RMB245.6 millionfor the year ended December 31, 2024. 2 0 2 41 2310 . 6 22 0 2 31 2310.57 –The Board recommends the payment of a final dividendof RMB0.62 per Share (tax inclusive) for the year endedDecember31,2024(a final dividend of RMB0.57 perShare(tax inclusive)for the year ended December 31,2023). Financial Highlights (1)2010122024482024523202448202441920242024123120232023 (1)Accordingto the“Consultation Conclusions on AcceptanceofMainland Accounting and Auditing Standards and MainlandAudit Firms for Mainland Incorporated Companies Listed in HongKong()”publishedbythe Stock Exchange in December 2010,PRC incorporatedissuers listed in Hong Kong are allowed to prepare their financialstatements in accordance with the China Accounting StandardsforBusiness